Spleen tyrosine kinase (SYK)
Spleen associated tyrosine kinase, commonly abbreviated as SYK, is a non-receptor tyrosine kinase with major roles in immune-cell signaling and inflammatory responses.
Spleen associated tyrosine kinase, commonly abbreviated as SYK, is a non-receptor tyrosine kinase with major roles in immune-cell signaling and inflammatory responses. It is widely studied as a therapeutic target because of its involvement in pathways that regulate activation of immune cells, cytokine production, and downstream inflammatory signaling. In biomedical research, SYK is often discussed in the context of diseases driven by immune dysregulation, including autoimmune disorders, inflammatory airway disease, ocular surface inflammation, hematologic malignancies, and other conditions in which aberrant signaling contributes to pathology.
As a drug target, SYK has attracted interest both as a standalone target and as part of dual-target strategies. Recent studies have evaluated SYK inhibitors in combination with other mechanisms, including HDAC inhibition in acute myeloid leukemia and VEGFR-2 inhibition in dry eye disease. These efforts reflect the broader therapeutic rationale for modulating SYK-mediated signaling to reduce inflammation or impair disease-promoting cellular programs.
Where the papers sit
11 papers from the last 6 months study Spleen tyrosine kinase (SYK) directly · updated from PubMed 15 Nov 2026
Study type 1 clinical trial · 1 human data · 9 preclinical
Themes no clear themes
Those 11 do not share a common subject.
-
SYK is examined across cancer, allergy, infection, transplantation, neurodegeneration and kidney disease. Reported effects include altered macrophage, mast-cell, microglial and inflammatory signaling. Fostamatinib and other SYK inhibitors recur alongside natural compounds, engineered cells and computational repositioning. The subjects and endpoints are too diverse to support a shared therapeutic direction.
Papers
The 11 papers from the last 6 months that study Spleen tyrosine kinase (SYK) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (11)
- CD19 CAR-macrophage suppressed the progression of DLBCL via modulating SYK/SHP2/TBK1/TFEB signaling. Biochemical and biophysical research communications · 7 Aug 2026 PMID 42566996
- Apigenin-7-O-β-D-glucuronide prophylaxis ameliorates allergic airway inflammation by suppressing the TCF4-mediated Syk pathway. International immunopharmacology · 1 Aug 2026 PMID 42541832
- Effect of Aronia melanocarpa extracts on allergic responses in mast cells. Bioscience, biotechnology, and biochemistry · 20 Jul 2026 PMID 42474209
- Syk from M1 macrophage exosomes drives vascular injury in kidney transplant rejection. Transplant immunology · 13 Jul 2026 PMID 42442616
- In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia-Telangiectasia. Chemical biology & drug design · 1 Jul 2026 PMID 42384606
- Coordinated Regulation of TLR2 Signaling by Neu1 Sialidase and the Siglec-5/Siglec-14 Receptor Pair During Mycoplasma pneumoniae Infection. ACS infectious diseases · 25 Jun 2026 PMID 42350323
- Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Critical care explorations · 22 Jun 2026 PMID 42329789
- Chrysin reprograms microglial metabolism and function via targeting SYK to alleviate the symptoms of Alzheimer's disease. Journal of ethnopharmacology · 20 Jun 2026 PMID 42322864
- Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation. Journal of medicinal chemistry · 9 Jun 2026 PMID 42262889
- Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazine derivatives as potent SYK inhibitors for solid tumor therapy. Bioorganic chemistry · 25 May 2026 PMID 42184580
- Identification of diagnostic markers for diabetic kidney disease by weighted gene co‑expression network analysis and machine learning. International journal of molecular medicine · 22 May 2026 PMID 42169644
By study type
Clinical trials (1)
- Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Critical care explorations · 22 Jun 2026 PMID 42329789
Human data, design not indexed (1)
- In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia-Telangiectasia. Chemical biology & drug design · 1 Jul 2026 PMID 42384606
Preclinical: animal, cell and lab studies (9)
- CD19 CAR-macrophage suppressed the progression of DLBCL via modulating SYK/SHP2/TBK1/TFEB signaling. Biochemical and biophysical research communications · 7 Aug 2026 PMID 42566996
- Apigenin-7-O-β-D-glucuronide prophylaxis ameliorates allergic airway inflammation by suppressing the TCF4-mediated Syk pathway. International immunopharmacology · 1 Aug 2026 PMID 42541832
- Effect of Aronia melanocarpa extracts on allergic responses in mast cells. Bioscience, biotechnology, and biochemistry · 20 Jul 2026 PMID 42474209
- Syk from M1 macrophage exosomes drives vascular injury in kidney transplant rejection. Transplant immunology · 13 Jul 2026 PMID 42442616
- Coordinated Regulation of TLR2 Signaling by Neu1 Sialidase and the Siglec-5/Siglec-14 Receptor Pair During Mycoplasma pneumoniae Infection. ACS infectious diseases · 25 Jun 2026 PMID 42350323
- Chrysin reprograms microglial metabolism and function via targeting SYK to alleviate the symptoms of Alzheimer's disease. Journal of ethnopharmacology · 20 Jun 2026 PMID 42322864
- Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation. Journal of medicinal chemistry · 9 Jun 2026 PMID 42262889
- Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazine derivatives as potent SYK inhibitors for solid tumor therapy. Bioorganic chemistry · 25 May 2026 PMID 42184580
- Identification of diagnostic markers for diabetic kidney disease by weighted gene co‑expression network analysis and machine learning. International journal of molecular medicine · 22 May 2026 PMID 42169644
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-26. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.